Evidence for the benefits of nonantipsychotic pharmacological augmentation in the treatment of depression

Chia Ming Chang, Soichiro Sato, Changsu Han

    Research output: Contribution to journalReview articlepeer-review

    18 Citations (Scopus)

    Abstract

    Failure to achieve an adequate response after initial antidepressant treatment in patients with depression is common and remains a clinical challenge. In recent years, some atypical antipsychotic agents have been approved by the US Food and Drug Administration for use in an augmentation strategy for major depressive disorder, and other agents are already in common use in clinical practice. We conducted a search of MEDLINE for relevant studies of augmentation strategies using randomized controlled trials and meta-analyses, and we summarize and discuss the various agents other than atypical antipsychotics. Lithium and thyroid hormone augmentation may improve the response of tricyclic antidepressants but not that of selective serotonin reuptake inhibitors. The efficacy of augmentation with modafinil, buspirone, methylphenidate, folic acid, pindolol and lamotrigine is limited or equivocal. Most of the studies have not focused on treatment-resistant depression (TRD). More trials are needed to help develop evidence-based options for augmentation in TRD.

    Original languageEnglish
    Pages (from-to)S21-S27
    JournalCNS Drugs
    Volume27
    Issue numberSUPPL.1
    DOIs
    Publication statusPublished - 2013 May

    ASJC Scopus subject areas

    • Clinical Neurology
    • Psychiatry and Mental health
    • Pharmacology (medical)

    Fingerprint

    Dive into the research topics of 'Evidence for the benefits of nonantipsychotic pharmacological augmentation in the treatment of depression'. Together they form a unique fingerprint.

    Cite this